CTLA4 and neoplasm: Moreover, compared to dual PD-1 and CTLA-4 checkpoint blockade combinations in CC treatment, such as the CheckMate 358 study (29) and a Phase II trial of balstilimab and zalifrelimab combination (NCT03495882) (30), cadonilimab showed a more favorable anti-tumor power with higher ORR and lower toxicity, underscoring its enormous potential in CC management.